1998
Incidence and clinical significance of false-negative sextant biopsies of the prostate.
Rabbani F, Stroumbakis N, Kava B, Cookson M, Fair W. Incidence and clinical significance of false-negative sextant biopsies of the prostate. Die Urologie 1998, 37: 660. PMID: 9887497.Peer-Reviewed Original ResearchINCIDENCE AND CLINICAL SIGNIFICANCE OF FALSE-NEGATIVE SEXTANT PROSTATE BIOPSIES
RABBANI F, STROUMBAKIS N, KAVA B, COOKSON M, FAIR W. INCIDENCE AND CLINICAL SIGNIFICANCE OF FALSE-NEGATIVE SEXTANT PROSTATE BIOPSIES. Journal Of Urology 1998, 159: 1247-1250. PMID: 9507846, DOI: 10.1016/s0022-5347(01)63574-2.Peer-Reviewed Original ResearchConceptsSextant prostate biopsyFalse-negative biopsiesProstate biopsyClinical significancePathological parametersRadical prostatectomyRelapse-free survival rateNeoadjuvant hormonal therapyInitial clinical stagePositive repeat biopsyHormonal therapyMost patientsPatients 27Relapse rateRepeat biopsyClinical parametersClinical stageSextant biopsyTrue incidenceTreatment modalitiesSignificant cancerProstate cancerHigh incidenceBiopsySurvival rate
1997
RADICAL CYSTECTOMY IN THE OCTOGENARIAN
Stroumbakis N, Herr H, Cookson M, Fair W. RADICAL CYSTECTOMY IN THE OCTOGENARIAN. Journal Of Urology 1997, 158: 2113-2117. PMID: 9366325, DOI: 10.1016/s0022-5347(01)68171-0.Peer-Reviewed Original ResearchConceptsInvasive bladder cancerBladder cancerMedian performance statusOutcome of cystectomyUse of cystectomyMedian hospital stayPatients 80 yearsMore medical problemsMedian survival timePatients 78Surgery 66Acceptable morbidityHospital stayOperative mortalityComplication ratePerformance statusSurgical complicationsMedian ageRadical cystectomySurgical reasonsUrinary diversionMedical illnessIntensive careFunctional statusQuality survivalUreteral Carcinoma in Situ at Radical Cystectomy: Does the Margin Matter?
Silver D, Stroumbakis N, Russo P, Fair W, Herr H. Ureteral Carcinoma in Situ at Radical Cystectomy: Does the Margin Matter? Journal Of Urology 1997, 158: 768-771. DOI: 10.1016/s0022-5347(01)64312-x.Peer-Reviewed Original ResearchConceptsUreteral carcinomaRadical cystectomyCarcinoma recurrencePositive cytologyMargin statusBladder cancerBacillus Calmette-Guerin treatmentRenal pelvis/ureterConsecutive radical cystectomiesUpper tract carcinomaUpper tract recurrenceCancer-specific survivalMetastatic bladder cancerPositive urinary cytologyFrozen section examinationLack of morbidityBladder tumor stageExpectant managementTract recurrenceMedian followupUreteral resectionSpecific survivalNegative marginsBladder tumorsTumor stageUreteral Carcinoma in Situ at Radical Cystectomy
Silver D, Stroumbakis N, Russo P, Fair W, Herr H. Ureteral Carcinoma in Situ at Radical Cystectomy. Journal Of Urology 1997, 158: 768-771.. PMID: 9258077, DOI: 10.1097/00005392-199709000-00020.Peer-Reviewed Original ResearchConceptsUreteral carcinomaRadical cystectomyCarcinoma recurrencePositive cytologyMargin statusBladder cancerBacillus Calmette-Guerin treatmentRenal pelvis/ureterConsecutive radical cystectomiesUpper tract carcinomaUpper tract recurrenceCancer-specific survivalMetastatic bladder cancerPositive urinary cytologyFrozen section examinationLack of morbidityBladder tumor stageUreteral marginsExpectant managementTract recurrenceMedian followupSpecific survivalUreteral resectionNegative marginsBladder tumorsEvaluating neoadjuvant therapy effectiveness on systemic disease: Use of a prostatic-specific membrane reverse transcription polymerase chain reaction
Su S, Heston W, Perroti M, Cookson M, Stroumbakis N, Huyrk R, Edwards E, Brander B, Coke J, Soloway S, Lewis A, Fair W. Evaluating neoadjuvant therapy effectiveness on systemic disease: Use of a prostatic-specific membrane reverse transcription polymerase chain reaction. Urology 1997, 49: 95-101. PMID: 9123743, DOI: 10.1016/s0090-4295(97)00175-1.Peer-Reviewed Original ResearchConceptsProstatic specific membrane antigenAndrogen deprivation therapyNeoadjuvant androgen deprivation therapyADT groupReverse transcription-polymerase chain reactionDeprivation therapyTranscription-polymerase chain reactionControl groupProstatic cellsTumor cellsPT2 patientsPT3 patientsSystemic diseasePolymerase chain reactionEffectiveness of ADTMemorial Sloan-Kettering Cancer CenterSerum PSA valuesProstate cancer patientsChain reactionHigher positive rateProstatic epithelial cellsPT3 lesionsControl patientsExtraprostatic diseaseAdditional patientsClinical significance of repeat sextant biopsies in prostate cancer patients
Stroumbakis N, Cookson M, Reuter V, Fair W. Clinical significance of repeat sextant biopsies in prostate cancer patients. Urology 1997, 49: 113-118. PMID: 9123730, DOI: 10.1016/s0090-4295(97)00178-7.Peer-Reviewed Original ResearchConceptsProstate-specific antigenOrgan-confined rateMargin-positive rateProstate cancerPSA densityRebiopsy resultsRepeat biopsySextant biopsyFinal surgical margin statusRandom systematic core biopsiesGreater prostate volumeNegative repeat biopsyAndrogen deprivation therapySurgical margin statusLower clinical stageProstate cancer patientsSignificant prostate cancerBiopsy-proven prostate cancerDeprivation therapyPositive rebiopsyConsecutive patientsInitial biopsyMargin statusProstate volumeT stageThe indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results
Fair W, Cookson M, Stroumbakis N, Cohen D, Aprikian A, Wang Y, Russo P, Soloway S, Sogani P, Sheinfeld J, Herr H, Dalgabni G, Begg C, Heston W, Reuter V. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology 1997, 49: 46-55. PMID: 9123736, DOI: 10.1016/s0090-4295(97)00169-6.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapyMargin-positive rateADT groupPathologic stagingRadical prostatectomyProstatic cancerMonths of ADTControl groupNeoadjuvant androgen deprivation therapyPreoperative androgen deprivation therapyDisease-free survival ratesDisease-free rateMonths of goserelinNeoadjuvant androgen deprivationPSA failure ratesPhase II studySubset of patientsAdditional therapeutic interventionsArea of oncologyDefinitive surgeryDeprivation therapyNeoadjuvant chemotherapyPSA failureBiochemical failureControl patients
1995
Metastatic breast cancer to the bladder: A case report
Schneidau T, Stroumbakis N, Choudhury M, Eshgi M, Mallouh C. Metastatic breast cancer to the bladder: A case report. International Urology And Nephrology 1995, 27: 297-300. PMID: 7591593, DOI: 10.1007/bf02564765.Peer-Reviewed Original Research
1993
Squamous cell carcinoma arising from suprapubic cystotomy site without bladder involvement
Stroumbakis N, Choudhury M, Hernandez-Graulau J. Squamous cell carcinoma arising from suprapubic cystotomy site without bladder involvement. Urology 1993, 41: 568-570. PMID: 8516995, DOI: 10.1016/0090-4295(93)90107-l.Peer-Reviewed Original Research
1992
Intrarenal endosurgery using the Hulbert electrosurgical knife for treatment of primary ureteropelvic junction obstruction.
Hernández-Graulau J, Stroumbakis N. Intrarenal endosurgery using the Hulbert electrosurgical knife for treatment of primary ureteropelvic junction obstruction. Urologic Oncology Seminars And Original Investigations 1992, 10: 248-51. PMID: 1485069.Peer-Reviewed Original ResearchThe future of laparoscopy in urologic surgery.
Stroumbakis N, Hernández-Graulau J. The future of laparoscopy in urologic surgery. Urologic Oncology Seminars And Original Investigations 1992, 10: 141-5. PMID: 1387966.Peer-Reviewed Original Research
1991
Heterotopic pregnancy involving the ovary and uterus following ovulation induction: diagnosis and management.
Stroumbakis N, Feldman M. Heterotopic pregnancy involving the ovary and uterus following ovulation induction: diagnosis and management. Connecticut Medicine 1991, 55: 195-9. PMID: 2070604.Peer-Reviewed Original Research